CellaVision's New CEO Drives Commercial Focus as Bone Marrow and Americas Momentum Take Hold

Q2 2026 marked a pivotal quarter for CellaVision, with net sales of SEK 200 million (+4.5% YoY, +5.6% organic) and a record performance in the Americas. More importantly, the quarter also marked the arrival of new CEO Steve Ferguson, whose focus on commercial execution signals a strategic shift as the company looks to capitalize on its innovation pipeline, particularly the Bone Marrow Aspirate Application.

A New CEO with a Commercial Mandate

Steve Ferguson, who took the helm on June 5th, brought 25 years of life science and diagnostic leadership. His first call emphasized partnership and market expansion. He stated: “We want to invest more in that relationship... There are other segments out there and other laboratory segments where perhaps our partner is not playing that I would like to get closer to.” — Steve Ferguson, Chief Executive Officer · 2026-07-17 This aligns with his broader message on commercial execution, a keyword that has spiked in the company's own trajectory. The company's keyword trajectory shows "commercial execution" rising to prominence this quarter, a direct reflection of the new CEO's priorities.

Bone Marrow: The Next Growth Catalyst

The commercial launch of the Bone Marrow Aspirate Application in EMEA represents a key milestone. Ferguson noted: “The initial feedback... the number of evaluations and the customer reactions is extremely encouraging, and we still hold our position that by year-end, the bone marrow sales should account to 1%-2% growth.” — Steve Ferguson, Chief Executive Officer · 2026-07-17 This builds on prior commentary from then-CEO Simon Østergaard, who had laid out the launch plan: “We'll start sort of the SoMe campaign in this quarter in March... and then we will, of course, start to position our solutions in the – in Europe.” — Simon Østergaard · 2026-02-05 The U.S. FDA 510(k) clearance is expected before year-end, which could open a significant new market. The company's focus on FDA registration process is a key theme.

Record Americas Sales and Inventory Normalization

Americas hit an all-time high, driven by large instrument sales. Ferguson attributed this to robust demand in medium and large lab segments, with tender wins and instrument refreshes. He also addressed potential channel concerns: “There's no evidence there at the moment... If anything, it's the opposite with the inventory normalization that impacted us in EMEA.” — Steve Ferguson, Chief Executive Officer · 2026-07-17 This suggests that the Inventory adjustment that had weighed on prior quarters is now behind them. The company's keyword trajectory shows "Inventory adjustment" as a top theme this quarter, confirming its significance.

Financial and Operational Notes

EBITDA margin came in at 27%, including SEK 9 million in CEO transition costs. CFO Monica Jónsson noted that R&D capitalization would increase from Q3 as projects mature, which is a positive for reported R&D costs. The company also highlighted a tender win for the U.N., which boosted APAC sales.

I want to make sure that every laboratory everywhere in the world that has a microscope is aware of the CellaVision technology.

The new CEO's focus on commercial execution, coupled with the Bone Marrow catalyst and Americas momentum, positions CellaVision for a potentially transformative second half. With a strong balance sheet and a clear innovation roadmap, the company appears well-placed to build on its foundation in digital cell morphology.